Zevra Total Liab vs Net Receivables Analysis

ZVRA Stock

9.33 0.17 1.79%

Zevra Therapeutics financial indicator trend analysis is more than just analyzing Zevra Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zevra Therapeutics is a good investment. Please check the relationship between Zevra Therapeutics Total Liab and its Net Receivables accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.

Total Liab vs Net Receivables

Total Liab vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zevra Therapeutics Total Liab account and Net Receivables. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Zevra Therapeutics' Total Liab and Net Receivables is 0.42. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Zevra Therapeutics, assuming nothing else is changed. The correlation between historical values of Zevra Therapeutics' Total Liab and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Zevra Therapeutics are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Total Liab i.e., Zevra Therapeutics' Total Liab and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.42

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Net Receivables

Most indicators from Zevra Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zevra Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.At present, Zevra Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.39, whereas Tax Provision is forecasted to decline to (35.7 K).

	2021	2022	2023	2024 (projected)
Total Revenue	28.7M	10.5M	27.5M	20.4M
Interest Income	248K	760K	4.6M	4.8M

Total Revenue Interest Income

Zevra Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Net Receivables	Other Stockholder Equity	Short Term Debt	Short Term Investments	Inventory	Current Deferred Revenue
Total Assets		0.78	0.79	0.75	0.34	-0.38	-0.79	0.78	0.7	0.87	0.75	0.55	0.73	0.91	0.05	0.74	0.3	0.84	-0.54	0.09	0.87	0.9	0.71	0.14	0.84	0.05
Other Current Liab	0.78		0.97	0.49	0.12	-0.18	-0.7	0.95	0.25	0.97	0.96	0.38	0.17	0.76	-0.01	0.67	0.29	0.35	-0.3	0.04	0.94	0.73	0.96	-0.02	0.84	0.41
Total Current Liabilities	0.79	0.97		0.4	0.18	-0.05	-0.72	0.99	0.19	0.98	0.97	0.44	0.16	0.72	0.13	0.7	0.43	0.35	-0.33	0.19	0.96	0.72	0.98	0.07	0.86	0.43
Total Stockholder Equity	0.75	0.49	0.4		-0.07	-0.87	-0.41	0.4	0.82	0.56	0.41	0.13	0.7	0.84	-0.58	0.34	-0.38	0.73	-0.07	-0.54	0.5	0.67	0.41	-0.01	0.59	-0.12
Property Plant And Equipment Net	0.34	0.12	0.18	-0.07		0.34	-0.71	0.18	0.27	0.21	0.09	0.5	0.35	0.3	0.62	0.45	0.61	0.37	-0.69	0.73	0.27	0.55	0.04	-0.26	0.26	-0.46
Net Debt	-0.38	-0.18	-0.05	-0.87	0.34		0.07	-0.06	-0.74	-0.2	-0.1	0.08	-0.51	-0.56	0.8	-0.08	0.7	-0.47	-0.17	0.83	-0.1	-0.35	-0.09	0.23	-0.23	0.25
Retained Earnings	-0.79	-0.7	-0.72	-0.41	-0.71	0.07		-0.74	-0.53	-0.75	-0.65	-0.67	-0.48	-0.81	-0.3	-0.85	-0.51	-0.61	0.71	-0.39	-0.77	-0.95	-0.6	0.28	-0.79	0.13
Accounts Payable	0.78	0.95	0.99	0.4	0.18	-0.06	-0.74		0.2	0.97	0.96	0.46	0.16	0.74	0.11	0.72	0.42	0.35	-0.36	0.18	0.94	0.74	0.96	0.03	0.89	0.4
Cash	0.7	0.25	0.19	0.82	0.27	-0.74	-0.53	0.2		0.34	0.19	0.39	0.9	0.73	-0.25	0.44	-0.13	0.88	-0.43	-0.25	0.29	0.71	0.12	-0.21	0.38	-0.46
Non Current Assets Total	0.87	0.97	0.98	0.56	0.21	-0.2	-0.75	0.97	0.34		0.95	0.43	0.3	0.83	0.02	0.68	0.32	0.48	-0.34	0.1	0.97	0.8	0.95	0.08	0.9	0.34
Non Currrent Assets Other	0.75	0.96	0.97	0.41	0.09	-0.1	-0.65	0.96	0.19	0.95		0.44	0.13	0.69	0.07	0.63	0.37	0.31	-0.36	0.11	0.92	0.66	0.95	0.06	0.81	0.44
Other Assets	0.55	0.38	0.44	0.13	0.5	0.08	-0.67	0.46	0.39	0.43	0.44		0.46	0.47	0.49	0.65	0.66	0.57	-0.74	0.41	0.5	0.58	0.28	0.06	0.52	0.05
Cash And Short Term Investments	0.73	0.17	0.16	0.7	0.35	-0.51	-0.48	0.16	0.9	0.3	0.13	0.46		0.62	0.04	0.46	0.09	0.96	-0.55	0.01	0.32	0.64	0.06	0.15	0.36	-0.37
Common Stock Shares Outstanding	0.91	0.76	0.72	0.84	0.3	-0.56	-0.81	0.74	0.73	0.83	0.69	0.47	0.62		-0.21	0.69	0.04	0.73	-0.39	-0.13	0.8	0.95	0.66	-0.13	0.88	-0.06
Non Current Liabilities Total	0.05	-0.01	0.13	-0.58	0.62	0.8	-0.3	0.11	-0.25	0.02	0.07	0.49	0.04	-0.21		0.33	0.91	0.05	-0.65	0.96	0.13	0.05	0.0	0.2	-0.01	0.0
Other Current Assets	0.74	0.67	0.7	0.34	0.45	-0.08	-0.85	0.72	0.44	0.68	0.63	0.65	0.46	0.69	0.33		0.52	0.57	-0.66	0.31	0.75	0.82	0.6	-0.15	0.76	0.04
Total Liab	0.3	0.29	0.43	-0.38	0.61	0.7	-0.51	0.42	-0.13	0.32	0.37	0.66	0.09	0.04	0.91	0.52		0.22	-0.69	0.9	0.42	0.28	0.31	0.24	0.27	0.25
Total Current Assets	0.84	0.35	0.35	0.73	0.37	-0.47	-0.61	0.35	0.88	0.48	0.31	0.57	0.96	0.73	0.05	0.57	0.22		-0.58	0.05	0.5	0.74	0.25	0.19	0.53	-0.18
Common Stock	-0.54	-0.3	-0.33	-0.07	-0.69	-0.17	0.71	-0.36	-0.43	-0.34	-0.36	-0.74	-0.55	-0.39	-0.65	-0.66	-0.69	-0.58		-0.61	-0.4	-0.59	-0.16	0.09	-0.37	0.23
Short Long Term Debt Total	0.09	0.04	0.19	-0.54	0.73	0.83	-0.39	0.18	-0.25	0.1	0.11	0.41	0.01	-0.13	0.96	0.31	0.9	0.05	-0.61		0.19	0.14	0.07	0.15	0.07	-0.01
Net Receivables	0.87	0.94	0.96	0.5	0.27	-0.1	-0.77	0.94	0.29	0.97	0.92	0.5	0.32	0.8	0.13	0.75	0.42	0.5	-0.4	0.19		0.8	0.91	0.17	0.93	0.38
Other Stockholder Equity	0.9	0.73	0.72	0.67	0.55	-0.35	-0.95	0.74	0.71	0.8	0.66	0.58	0.64	0.95	0.05	0.82	0.28	0.74	-0.59	0.14	0.8		0.62	-0.22	0.85	-0.15
Short Term Debt	0.71	0.96	0.98	0.41	0.04	-0.09	-0.6	0.96	0.12	0.95	0.95	0.28	0.06	0.66	0.0	0.6	0.31	0.25	-0.16	0.07	0.91	0.62		0.09	0.8	0.5
Short Term Investments	0.14	-0.02	0.07	-0.01	-0.26	0.23	0.28	0.03	-0.21	0.08	0.06	0.06	0.15	-0.13	0.2	-0.15	0.24	0.19	0.09	0.15	0.17	-0.22	0.09		0.07	0.58
Inventory	0.84	0.84	0.86	0.59	0.26	-0.23	-0.79	0.89	0.38	0.9	0.81	0.52	0.36	0.88	-0.01	0.76	0.27	0.53	-0.37	0.07	0.93	0.85	0.8	0.07		0.26
Current Deferred Revenue	0.05	0.41	0.43	-0.12	-0.46	0.25	0.13	0.4	-0.46	0.34	0.44	0.05	-0.37	-0.06	0.0	0.04	0.25	-0.18	0.23	-0.01	0.38	-0.15	0.5	0.58	0.26

Click cells to compare fundamentals

Zevra Therapeutics Account Relationship Matchups

Zevra Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.5M	11.2M	132.9M	115.5M	172.3M	180.9M
Other Current Liab	236K	5.5M	3.3M	3.3M	21.5M	22.6M
Total Current Liabilities	5.4M	7.5M	4.2M	11.7M	73.7M	77.4M
Total Stockholder Equity	(74.5M)	(66.4M)	127.1M	85.8M	61.9M	65.0M
Property Plant And Equipment Net	3.0M	2.4M	2.0M	1.8M	1.5M	1.6M
Net Debt	76.3M	66.1M	(110.8M)	(51.3M)	716K	680.2K
Retained Earnings	(245.7M)	(258.5M)	(267.0M)	(308.6M)	(399.8M)	(379.8M)
Accounts Payable	1.1M	1.2M	516K	3.6M	14.0M	14.7M
Cash	3.2M	4.2M	112.3M	65.5M	43.0M	29.5M
Non Current Assets Total	3.9M	2.8M	17.9M	22.5M	85.4M	89.7M
Non Currrent Assets Other	562K	527K	438K	724K	9.9M	10.4M
Cash And Short Term Investments	3.2M	4.2M	112.3M	82.8M	43.0M	40.6M
Common Stock Shares Outstanding	1.9M	4.0M	29.8M	34.5M	35.5M	37.2M
Non Current Liabilities Total	79.5M	70.1M	1.6M	18.0M	36.7M	54.6M
Other Current Assets	1.6M	1.5M	1.2M	2.8M	3.1M	3.2M
Total Liab	85.0M	77.6M	5.8M	29.7M	110.5M	68.7M
Total Current Assets	6.6M	8.4M	115.1M	93.0M	86.9M	48.0M
Short Long Term Debt Total	79.5M	70.4M	1.6M	14.1M	43.8M	52.1M
Net Receivables	1.9M	2.6M	1.5M	7.2M	17.4M	18.2M
Liabilities And Stockholders Equity	10.5M	11.2M	132.9M	115.5M	172.3M	180.9M
Other Stockholder Equity	171.3M	192.1M	394.1M	428.7M	461.7M	484.8M
Short Term Debt	284K	889K	371K	1.4M	38.2M	40.2M
Short Term Investments	31.4M	3.3M	0.0	17.4M	24.7M	14.7M
Inventory	1.0	224K	109K	24.1M	27.7M	29.1M
Current Deferred Revenue	3.8M	5.5M	2.5M	4.7M	8.3M	5.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Zevra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zevra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zevra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zevra Therapeutics Stock:

How To Invest In Zevra

Details

Is Zevra Stock a good investment?

Details

What is Zevra Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zevra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zevra Therapeutics. If investors know Zevra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zevra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.13)

Revenue Per Share

0.575

Quarterly Revenue Growth

0.276

Return On Assets

(0.33)

Return On Equity

(1.31)

The market value of Zevra Therapeutics is measured differently than its book value, which is the value of Zevra that is recorded on the company's balance sheet. Investors also form their own opinion of Zevra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Zevra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zevra Therapeutics' market value can be influenced by many factors that don't directly affect Zevra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zevra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zevra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zevra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zevra Total Liab vs Net Receivables Analysis

Total Liab vs Net Receivables

Total Liab vs Net Receivables Correlation Analysis

Correlation Coefficient

Total Liab

Net Receivables

Zevra Therapeutics fundamental ratios Correlations

Zevra Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zevra Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accounts Payable	+ 0.99	Total Current Liabilities
Non Current Assets Total	+ 0.98	Total Current Liabilities
Short Term Debt	+ 0.98	Total Current Liabilities
Total Current Liabilities	+ 0.97	Other Current Liab
Non Current Assets Total	+ 0.97	Other Current Liab
Non Currrent Assets Other	+ 0.97	Total Current Liabilities

Other Stockholder Equity	- 0.95	Retained Earnings
Net Debt	- 0.87	Total Stockholder Equity
Other Current Assets	- 0.85	Retained Earnings
Common Stock Shares Outstanding	- 0.81	Retained Earnings
Inventory	- 0.79	Retained Earnings
Retained Earnings	- 0.79	Total Assets